



FY2023 Q2 Financial Results



Company

HEALIOS K.K. (TSE 4593)

Date

August 14, 2023

This material has been prepared solely for the purpose of disclosing relevant information regarding HEALIOS K.K. (“HEALIOS”). This document does not constitute an offer to sell or the solicitation of an offer to buy any security in the United States, Japan or any other jurisdiction.

This presentation contains statements that constitute forward-looking statements, including estimations, forecasts, targets and plans, and such forward-looking statements do not represent any guarantee by management of future performance. [In many cases, but not all, HEALIOS uses such words as “aim,” “anticipate,” “believe,” “continue,” “endeavor,” “estimate,” “expect,” “initiative,” “intend,” “may,” “plan,” “potential,” “probability,” “project,” “risk,” “seek,” “should,” “strive,” “target,” “will” and similar expressions to identify forward-looking statements.] You can also identify forward-looking statements by discussions of strategy, plans or intentions. Any forward-looking statements in this document are based on the current assumptions and beliefs of HEALIOS in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors may cause HEALIOS’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof, and HEALIOS does not guarantee that the information contained in this presentation is accurate or complete. It should be understood that subsequent developments may affect the information contained in this presentation, which HEALIOS is not under an obligation, or does not plan, to update, revise or affirm. The information in this presentation is subject to change without prior notice and such information may change materially. Neither this presentation nor any of its contents may be disclosed to or used by any other party for any purpose without the prior written consent of HEALIOS.


The information in connection with or prepared by companies or parties other than HEALIOS is based on publicly available and other information as cited, and HEALIOS does not have independently verified the accuracy and appropriateness of, nor makes any warranties with respect to, such information.

The information about regenerative medicine products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.




Contents

| | |
|-------------------------------------------------------------|----|
| 1. Strategy/Pipeline | 03 |
| 2. Financial Highlights | 13 |
| 3. HLCM051 ARDS | 17 |
| 4. HLCM051 Stroke | 23 |
| 5. HLCN061 iPSC eNK Cells | 29 |
| 6. Universal Donor Cell / Platform Replacement Therapies | 35 |
| 7. Conclusion | 43 |
| 8. Appendix | 44 |

A grayscale background image of a long, straight road stretching into the distance, flanked by rolling hills under a bright sky. The road has white dashed lines and a white dashed line in the center. The text is overlaid on this image.

To become a global biopharma company committed to transforming the lives of patients by creating, developing and commercializing cutting edge cell therapy technologies.

*Healios is leading the research and development of cellular medicines focused on major causes of death and areas of unmet medical need in developed countries
— oncology: solid tumors; CNS: ischemic stroke; respiratory: ARDS—*



¹Future migration to UDC platform

Inflammatory Conditions

Ischemic stroke

HLCM051

- Athersys plans to disclose an interim analysis*¹ of the global clinical trial*² in early October*³.
- We are discussing with PMDA to utilize clinical trial data / to participate in the global trial.

*1 An analysis performed by an independent statistician during the course of a clinical trial. The results can be used to revise the number of patients required.

*2 A phase III study for stroke in the U.S conducted by Athersys. (MASTERS-2 study)

*3 As per Athersys announcement on August 9, 2023.

ARDS

- Use of 3D bioreactor-based manufacturing method produced product for additional study (small-scale double-blind study) .
- Project finance and subsidies anticipated to be used for development funds.

Immuno- Oncology

Solid tumors

eNK[®] (HLCN061) / CAR-eNK[®]

- Have established an effective eNK[®] platform for solid tumors.
- Clinical trial is scheduled to start in FY2025.

Replacement Therapies

RPE tear AMD


HLCR011

- Started phase 1/2 study in RPE tears using RPE cells derived from allogeneic iPS cells in June, 2023.
- Scheduled to be launched in 2025 (announced by Sumitomo Pharma).

*** All pipeline programs are in discussion with potential partners**

| | Development Code | Therapeutic Area | Therapy | Region | Discovery | Pre-Clinical | Clinical | Comments |
|-------------------------|------------------|------------------|---------------------------|--------|-----------|--------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Inflammatory Conditions | HLCM051 | Ischemic stroke | MultiStem® | Japan | Phase 2/3 | | | Ongoing consultations including utilization of clinical trial data / participation in global trial with regulatory authorities based on the discussion results with FDA SAKIGAKE designation |
| | HLCM051 | ARDS | MultiStem® | Japan | Phase 2 | | | Preparing to start clinical trial Orphan designation |
| Immuno-Oncology | HLCN061 | Solid tumors | eNK | Global | | | | Pre-IND started IND: 2025 Joint research with National Cancer Center Japan, Hiroshima University and Hyogo Medical University |
| | – | | CAR-eNK | Global | | | | |
| Replacement Therapies | HLCR011 | RPE tear AMD | RPE | Japan | Phase 1/2 | | | Started phase 1 / 2 study in RPE tears in June 2023 with Sumitomo Pharma Co., Ltd. Scheduled to be launched in FY2025 (planned by Sumitomo Pharma) |
| | – | Retinal disease | UDC-photoreceptors & RPE* | Global | | | | |
| | HLCL041 | Liver disease | Liver buds | Global | | | | Carve-out plan to accelerate R&D and efficiently advance the program |
| | – | Diabetes | UDC-pancreatic islets | Global | | | | |

Leverage external funds and promote research and development of highly promising seeds



R&D of ARDS


| | |
|---------------|------------------------------------------------------------|
| Name | ProcellCure Inc. |
| Headquarters | Chuo-ku, Kobe, Hyogo, Japan |
| Business | Research, development and sales of pharmaceutical products |
| Establishment | July 24, 2023 |

R&D of eNK cells

| | |
|---------------|---------------------------------------------------------------------------|
| Name | eNK Therapeutics Inc. |
| Headquarters | Chiyoda-ku, Tokyo, Japan |
| Business | Research, development, manufacturing and sales of pharmaceutical products |
| Establishment | August 14, 2023 |

| Basic policy


Promote R&D while maximizing investment efficiency and optimizing costs, using own funds and external funds such as project finance, partnering, etc.



An RPE (Retinal pigment epithelium) tear is a disease in which the sensory retina is detached from the RPE due to a tear in the retina (retinal tear). It causes visual field defects and vision loss.

If RPE is defective but photoreceptor function is preserved, pigment epithelial cell transplantation can restore vision.

RPE tear



Joint Development


- In Japan, HEALIOS and Sumitomo Pharma Co., Ltd. are jointly developing a treatment using iPS cell-derived RPE cells.
- Started phase 1 / 2 study in June, 2023

| | |
|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Test product | HLCR011: iPS cell-derived retinal pigment epithelial (RPE) cells suspension |
| Development stage | Phase 1/2 |
| Subjects | Patients with retinal pigment epithelium tears |
| Design for the clinical study (target number of cases) | Part 1: Unmasked, uncontrolled (one HLA-mismatched subject) Part 2: Unmasked, randomized (treatment/observation groups, 10 subjects/group, total 20 subjects) |
| Primary endpoint | Safety of subretinal administration of HLCR011 in patients with RPE tears (number and ratio of subjects with observed adverse events) |
| Secondary endpoint (efficacy) | Visual function evaluation |

The clinical study is a multicenter, unmasked, randomized study. Sumitomo Pharma is now selecting clinical study sites. Subjects will be enrolled immediately after the completion of the preparation, including conclusion of contracts with the clinical study sites.

3D bioreactor-based manufacturing method

- Agreed with PMDA to use investigational product manufactured by 3D bioreactor-based method, which enables mass production, for ARDS clinical trials.
- Compared to the conventional 2D method, a large and stable supply of products can be achieved in commercial production after the product is launched.
- Cost-effectiveness and superior economics can be expected with the 3D method



HLCM051 could be a pioneer as a 3D bioreactor-approved cell product.

Note: At the time of publication, there are no approved allogeneic cell products that have been publicly announced to be manufactured in 3D bioreactor-based method (according to our own research).



Financial Highlights

R&D expenses for the six months ended June 30, 2023 were 1,047 million yen (**R&D expenses of approximately 45% of the same period of the previous year**). Continue to advance R&D activities while optimizing investment efficiency and expense discipline.

(Units: millions of yen)

| | FY2022 Q2(YTD) | FY2023 Q2(YTD) | | |
|---------------------|-------------------|----------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| | | | YoY variance | Main reasons for increase/decrease |
| Revenue | 22 | 108 | 86 | |
| Operating profit | -3,064 | -1,555 | 1,510 | Decrease in SG&A expenses + 134 Decrease in R&D expenses +1,289 |
| Profit | -3,260 | -1,384 | 1,877 | Increase in finance income + 57 Decrease in finance costs +329 (Primarily non-cash activity; please refer to the next page for details) |
| R&D expenses | 2,336 | 1,047 | -1,289 | |
| Number of employees | 110 | 63 | -47 | |

(Note)

* For details of the financial figures, please refer to the summary of the financial results announced today.

Details of finance income and finance costs

In the six months ended June 30, 2023, we recorded finance income of ¥308 million and finance costs of ¥74 million.

Finance income was mainly due to the recording of ¥230 million in profit or loss transferred to equity interests held by external investors in the Saisei Fund ^{*1} and ¥ 61 million in foreign exchange gains.

Finance costs were mainly due to the recording of ¥55 million in interest expenses on bonds ^{*2} and ¥19 million in interest expenses.

*1. Profit or loss transferred to equity interests held by external investors in the Saisei Fund

Profit or loss transferred to equity interests held by external investors in the Saisei Fund is the transfer amount of profits and losses of Saisei Bioventures, L.P., the consolidated subsidiary of our company, to limited partners other than our company. Saisei Bioventures, L.P. is a limited partnership established by Saisei Capital Ltd., the general partner and consolidated subsidiary of our company.

*2. Interest expenses on bonds

Of the total interest on bonds of 55 million yen posted for the six months ended June 30, 2023, 35 million yen was charged to income using the amortized cost method. This is a non-cash expense recorded in accordance with the International Financial Reporting Standards (IFRS), which was introduced in the 1st quarter of the fiscal year ended December 2020.

Under JGAAP, convertible bond issuances were accounted for as liabilities and issue fees were accounted for as expenses. Under IFRS, however, proceeds, after deducting issue fees from convertible bond issuances, are accounted for as liabilities and equity, based on a certain standard. As a result, the difference between the face value of convertible bonds and the amount recorded as liabilities is amortized (expensed) over the period.


Consolidated Statement of Financial Position

(Units: millions of yen)

| | | December 31, 2022 | June 30, 2023 | | |
|------------------------------|-------------------------|--------------------|--------------------|----------|-----------------------------------------------------------------------------------------------------------|
| | | | | Variance | Main reasons for increase/decrease |
| | Current assets | 8,462 (56.3%) | 7,804 (53.1%) | -658 | Decrease in cash and cash equivalents -321 (Cash and cash equivalent balance at 6/30/23 was 6,926) |
| | Non-current assets | 6,571 (43.7%) | 6,886 (46.9%) | 316 | Increase in other financial assets +669 Decrease in investments accounted for using equity method -150 |
| Total assets | | 15,033 (100.0%) | 14,691 (100.0%) | -342 | |
| | Current liabilities | 3,808 (25.3%) | 3,474 (23.6%) | -334 | |
| | Non-current liabilities | 6,842 (45.5%) | 7,959 (54.2%) | 1,117 | Increase in equity interests held by external investors in Saisei Fund +1,105 |
| Total liabilities | | 10,650 (70.8%) | 11,433 (77.8%) | 783 | |
| Total equity | | 4,382 (29.2%) | 3,258 (22.2%) | -1,125 | Recording of loss -1,384 |
| Total liabilities and equity | | 15,033 (100.0%) | 14,691 (100.0%) | -342 | |

(Note) For details of the financial figures, please refer to the summary of the financial results announced today.

MultiStem® Inflammatory Conditions




Development plan

Inflammatory Conditions

ARDS

In discussions with potential partner companies

- Use of 3D bioreactor-based manufacturing method produced product for additional study (small-scale double-blind study) .
- Project finance and subsidies anticipated to be used for development funds.



HLCM051 has been designated as an **orphan regenerative medicine product** for use in the treatment of ARDS by the Ministry of Health, Labor and Welfare. (It has received SAKIGAKE status for ischemic stroke.)

| | |
|-------------------------------|------------------------------------------------------------------------------------------------------------|
| Conditions | Placebo-Controlled, Double-Blind, Randomized |
| Subjects | Patients with pneumonia-induced ARDS *Including patients with pneumonia-induced ARDS caused by COVID-19 |
| Enrollment | 80 (HLKM051 [n=40], placebo [n=40]) |
| Primary Endpoint | VFD (the number of days out of 28 during which a ventilator was not used for the patient) |
| Secondary Endpoint (examples) | Mortality (180 days after administration) |

The trial protocol will be finalized upon the submission of a future IND.

There is demand for new treatments for ARDS that will lead to improvements in patients' symptoms and prognosis

The number of ARDS patients in Japan is estimated at approximately 28,000 per year*¹

About ARDS*²

Acute Respiratory Distress Syndrome (ARDS) is a **general term for the symptoms of acute respiratory failure** suddenly occurring in all seriously ill patients.

The mortality rate is approximately 30 to 58%*².

Approximately 1/3 of ARDS cases are caused by pneumonia.

ARDS is a common cause of morbidity and mortality in severe COVID-19.

Current Treatment

At present, **there are no therapeutic drugs** that can make a direct improvement to a patient's vital prognosis when ARDS develops.

The only symptomatic treatment for respiratory failure includes artificial respiration.



(Source) Athersys


(source)

* 1 The number of ARDS patients in Japan is estimated by Healios based on the incidence rate of epidemiological data and the total demographical population in Japan.

* 2 ARDS treatment guideline 2016

Phase II study investigating the efficacy and safety of HLCM051 in pneumonia induced ARDS patients

ARDS trial cohorts



Patient enrollment of COVID-19 pneumonia-derived cases (Cohort 2) was performed separately from the conventional clinical trial administration group (Cohort 1).

Cohort 1

No safety concerns.

The HLCM051 treated group demonstrated a 9-day higher median VFD than the standard therapy group.

The treated group saw a 39% reduction in mortality as compared to patients treated with standard therapy.

Cohort 2

No deaths, no safety concerns.

The ventilator was withdrawn within 28 days for all five patients and in three days or less for three of these patients.

| | Cohort 1 | |
|-------------------------------------------------------------------------------------------|----------------|------------------|
| | HLCM051 | Standard therapy |
| Primary Endpoint | | |
| VFD (the number of days out of 28 during which a ventilator was not used for the patient) | 20 days | 11 days |
| Secondary Endpoint | | |
| Mortality (180 days after administration) | 26.3% | 42.9% |

| | Cohort 2 |
|-------------------------------------------|-------------------------|
| | HLCM051 |
| Primary Endpoint | |
| Safety | No safety issues |
| Secondary Endpoint | |
| VFD | 25 days |
| Mortality (180 days after administration) | 0% |


TREASURE study

- Inflammatory Conditions
- Ischemic stroke

In discussions with potential partner companies

- Athersys plans to announce interim analysis*¹ of the global clinical trial*² in early October*³.
- We are discussing with PMDA to utilize clinical trial data / participate in the global trial.


*1 An analysis performed by an independent statistician during the course of a clinical trial. The results can be used to redefine the number of patients required.
 *2 A phase III study for stroke in the U.S conducted by Athersys. (MASTERS-2 study)
 *3 As per Athersys announcement on August 9, 2023.



• HLCM051 is designated for SAKIGAKE Designation System

Expected development of a new therapy that can be applied in a longer treatment window period following the onset of ischemic stroke (ability to help more patients)

Treatment in Accordance with the Period After Onset



※1 Dissolves blood clots in the brain vessels

※2 Insertion of the catheter into a blood vessel and recovery of the thrombus directly with a wire.

(Note) This material was prepared to explicitly describe the major therapeutic options for ischemic stroke and their treatment window periods after onset. Appropriate treatments are conducted according to patients' conditions and classification of their symptoms. Experimental or investigational treatments not included in the above are also performed.

Ischemic Stroke

Ischemic stroke, which represents the most common form of stroke (70 - 75% of cases in Japan), is caused by a blockage of blood flow in the brain that cuts off the supply of oxygen and nutrients, resulting in tissue loss.



(Source) Athersys

It is estimated that 37.9% of bedridden patients and 21.7% of persons who were in need of care were affected by ischemic stroke.

| | |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Trial | Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 in Patients With Ischemic Stroke (TREASURE study) |
| Subjects | Ischemic stroke within 18 to 36 hours |
| Conditions | Placebo-Controlled, Double-Blind |
| Enrollment | 220 (HLCM051 [n=110], placebo [n=110], randomized) |
| Outcome Measures (examples) | <ul style="list-style-type: none">• Proportion of subjects achieving Excellent Outcome defined by functional assessments (primary endpoint at day 90)• Global recovery (i.e., GEE) and dichotomous assessment• Proportion of subjects with a BI score of ≥ 95 |

Comparison of results between the HLCM051 group and the placebo group at 90 and 365 days


| | 90 days | | | 365 days | | |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------|---------------|---------|---------------|---------------|----------------|
| | HLCM051 | Placebo | p-value | HLCM051 | Placebo | p-value |
| Excellent Outcome^{*1} | 12 (11.5%) | 10 (9.8%) | p=0.903 | 16 (15.4%) | 11 (10.8%) | p=0.431 |
| Global Recovery^{*2} | 20 (19.2%) | 16 (15.7%) | p=0.762 | 29 (27.9%) | 16 (15.7%) | p=0.037 |
| BI >=95 | 31 (29.8%) | 24 (23.5%) | p=0.437 | 37 (35.6%) | 23 (22.5%) | p=0.045 |
| Safety outcomes | There were no significant differences, including mortality and adverse events between the treatment and placebo groups. | | | | | |

*1 Global Recovery (mRS<=2, NIHSS change >=75% and Barthel Index>=95).

*2 Excellent Outcome (mRS<=1, NIHSS<=1 and Barthel Index>=95)

* The above data was presented at the 14th World Stroke Conference and the 40th Annual Meeting of Japan Society of Neurological Therapeutics

- 1 The results showed a trend toward efficacy as cerebral infarct volume increased from 25 mL to 50 mL and 75 mL. The efficacy was statistically significant, especially for volumes of 50 mL or greater.
- 2 Though a small sample size, patients under 64 years of age appear to achieve better results.



* The subgroup analysis results were presented at the 48th Annual Meeting of the Japanese Stroke Association held on March 17, 2023.

- TREASURE Study (Ischemic Stroke)


Athersys plans to disclose an interim analysis of the global clinical trial in early October.


We are discussing with PMDA in relation to the utilization of global clinical trial data / participation in the global trial.

- ONE-BRIDGE Study (ARDS)

The design of an additional small-scale double-blind study was agreed upon with the PMDA and we have reached an agreement to use investigational product manufactured by our 3D bioreactor-based method in the next additional study. We are preparing to start the clinical trial.


iPSC eNK Immuno-Oncology





HLCN061: eNK Cells Enhanced Not Only with Improved Cytotoxicity and Persistence, but with Greater Migration to Tumors and Recruitment of Host Immune Cells

Healios' eNK Cells key features



*ADCC: antibody-dependent cellular cytotoxicity
Attack activity to pathogens by an immune cell through an antibody


-GMP facility fully operational and being advanced in preparation for clinical trials
-In-house manufacturing enables control of the schedule and quality of clinical production




Fully-closed, feeder free, 3D perfusion bioreactor system




KCMI; Kobe Center for Medical Innovation
 Photo by: OM Kobe (KCMI management company)



**100 billion
eNK cells per batch**




**Cryopreserved samples show
high cytotoxicity post thaw**





- **Years of Experience have Yielded a Best-In-Class Platform:** Healios' iPSC therapy leadership has led to the development of a functionally enhanced natural killer cell platform which provides for multiple pipeline product opportunities
- **Unique Approach:** Our eNK cell platform has enhanced recognition, cytotoxicity, and persistence, as well as unique recruitment and trafficking properties, designed to infiltrate solid tumors and mount a whole system immune cell attack
- **Promising *In Vitro* and *In Vivo* Evidence** demonstrating robust cancer elimination
- **Initial Target Indications:** Lung cancer, liver cancer, mesothelioma, other non-disclosed
- **Robust and Advanced Manufacturing** processes and infrastructure in place
- **Strong team** with near-term regulatory milestones: Pre-IND: 2022, IND: 2025
- **Pursuing partnerships** to bring new treatments to cancer patients as soon as possible
- **Funding:** We have decided to establish a subsidiary to promote the development of eNK cells seeking capital from venture funds and other investors.

Universal Donor Cell (UDC) Replacement Therapies



¹Future migration to UDC platform

Gene Editing Procedure for Healios UDC




- Off-the-shelf, scalable and cost-efficient
- Address broadest population with single product
- Enhanced level and duration of efficacy

(Source) in-house data


Clinical grade line and Master Cell Bank established in 2020/2021

Healios UDC-derived otic neural progenitor cells (ONPs) demonstrate enhanced survival after transplantation into the cochlea confirmed by Northwestern University

Otic neural progenitor cells



Representative immunocytochemistry photomicrographs of iPSC-derived ONPs



Quantification of iPSC-derived ONPs 10 days following intracochlear transplantation

(Source: Northwestern University)

Left

Healios UDCs (hi-iPSCs) differentiated into late-stage ONPs as well as unedited cells (wt-iPSC) using multiple differentiation markers.

Right

More Healios UDC-derived ONPs (hi-ONPs) than unedited parental cell-derived ONPs (wt-ONPs) were viable after transplantation. In other words, immune rejection was reduced as expected.


The induction of differentiation into otic neural progenitor cells and the hypo-immune benefit upon transplantation into mice were confirmed

This approach may open a new avenue for experimental and clinical sensorineural hearing loss (SNHL) treatments




Supplying UDC and iPS cells to several companies and academic institutions (more than 10 facilities) and evaluating their potential for various diseases

Photoreceptor cells




UDC


Differentiation
and induction



Photoreceptor cells
From UDC



Joint Research with STEMAXON

Confirmation of differentiation and culture from UDCs to photoreceptor cells* for retinal disease


- Cone cell dominant photoreceptor cell sheets with color-sensing
- Minimal contamination of unnecessary cells such as bipolar cells, which can be an obstacle to improving visual acuity
- Recovery of visual function confirmed in transplantation experiments using animal disease models

* Photoreceptor cells are one of the cells that compose the retina and are particularly responsive to light.

(Source) Joint research data


Joint research with the Department of Regenerative Medicine at the National Center for Global Health and Medicine in Tokyo

| Pancreatic β -cells



UDC


Differentiation
and induction



UDC-derived
pancreatic β cells
(HE staining)

(Photo provided by the National Center
for Global Health and Medicine)

Pancreatic β -cells are a type of cell present in the islets of Langerhans within the pancreas. They produce and secrete insulin in response to blood glucose levels and serve to regulate the amount of glucose in the bloodstream.


In our joint research with the Department of Regenerative Medicine at the National Center for Global Health and Medicine in Tokyo, **we have successfully confirmed the differentiation of UDCs into pancreatic β -cells.**

Moving forward, our joint research will work on optimizing the process and verifying the efficacy and safety of these cells in animal models of diabetes. Through this achievement, we hope to develop a new more effective therapeutic approach for diabetes and further expand the value and impact of our company's iPSC platform

(Source) Joint research data


Age-related Macular Degeneration (AMD) causes Retinal Pigment Epithelial (RPE) cells to degenerate, which damages function

Regular Macular Part




Developed Dry-AMD

Immunity barrier maintained
→ Degeneration of photoreceptor → Dry AMD



Wet AMD

Destruction of immunity barrier → Invasion of immune cells
→ Inflammation → Wet AMD





Joint Development

In Japan, HEALIOS and Sumitomo Pharma Co., Ltd. are jointly developing a treatment using iPS cell-derived RPE cells.

After confirming the efficacy of the treatment in RPE tears, Sumitomo Pharma will consider expanding the indication to include AMD.


By creating an "Organ Bud" of each organ with iPS cells, we have laid the groundwork for paradigm shifting therapies to emerge for various severe diseases.

UDCs allow for the realization of organ replacement using organ buds.



Green : Cells of each organ
 Red : Vascular endothelial cell
 Black : MSC

Transplanted to mice



(Sours) Modified from Takebe T. et al., Cell Stem Cell, 2015

The vascularization was confirmed in vivo by transplantation to mice.

(Sours) Japan Science and Technology Agency Science News "Diverse Approaches in Regenerative Medicine from Cell to Tissue/Organ" (Distributed October 3, 2013)
<https://sciencechannel.jst.go.jp/M130001/detail/M130001005.html>

We plan to carve out the technology to efficiently accelerate R&D in collaboration with external partners such as venture capital funds.

- Focus pipeline and maximize investment efficiency.
 - Non-dilutive funding from project finance, carve outs, grants & partnering.
- Preparing for Multistem ARDS trial; continuing to establish efficient path for ischemic stroke.
- Establish subsidiaries to promote R&D pipeline.
 - ProcellCure Inc. (ARDS) / eNK Therapeutics (eNK cells)
- Driving forward eNK program towards the clinic while pursuing partnerships with global pharmaceutical companies.
- RPE trial started by Sumitomo Pharma; projected 2025 product launch.
- Expanding UDC and iPS cell line collaboration activities.

*Committed to transforming the lives of patients by
creating, developing and commercializing cutting edge cell therapy technologies*



Appendix

To become a global biopharma company committed to transforming the lives of patients by creating, developing and commercializing cutting edge cell therapy technologies.

About us

Company Overview

| | |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Company Name | HEALIOS K.K. |
| Representative | Hardy TS Kagimoto, MD, Chairman and CEO |
| Establishment | February 24, 2011 |
| Paid in Capital | 119 million yen (As of April 30, 2023) |
| Head office | Hibiya Mitsui Tower 12F, 1-1-2 Yurakucho, Chiyoda-ku ,Tokyo 100-0006, Japan |
| Number of Employees | 63 (As of June 30, 2023) |
| Business | Research, development and manufacturing of cell therapy/ regenerative medicine products |
| Affiliated Company | Sighregen Co., Ltd. (Joint Venture with Sumitomo Dainippon Pharma Co., Ltd.) |
| Subsidiary | <ul style="list-style-type: none"> • Healios NA Inc. (Established in February 2018) • Organoid Neogenesis Laboratory Inc. (June 2018 to promote the practical use of organ bud technology) • Saisei Ventures LLC (January 2021, as a venture fund investment advisor) • Saisei Capital Ltd. (January 2021 as a venture fund general partner) • Saisei Bioventures, L.P. (January 2021 as a venture fund limited partnership) • ProcellCure Inc. (July 2023 to promote development of ARDS) • eNK Therapeutics Inc. (August 2023 to promote R&D of eNK cells) |

Large number of researchers (24 Ph.D.'s as of Mar. 31) on staff and efficient, in-house implementation of everything from gene editing to process development

1. Exploratory Research

- I. Development of iPSC differentiation induction methods
- II. Functional evaluation of iPSC derived cells
- III. Functional evaluation of iPSC derived cells
- IV. Evaluation of gene-edited cells

2. QC

- I. Functional evaluation of various cells
- II. Development of evaluation protocols

3. Genetic Recombination Experiments

- I. Construction of plasmids
- II. Construction of viral vectors
- III. Creation of transgenic cells




Healios' Kobe Institute Area (Photo by Kobe Urban Promotion Service Co.,Ltd.)

4. Experiments on animals

- I. Generation of disease mice models
- II. Evaluation of antitumor effects *in vivo*
- III. Evaluation of immune response *in vivo*
- IV. Evaluation: tissue section and immunostaining

5. Process Development Research

- I. Optimization of differentiation
- II. Development of mass production methods
- III. Development of freezing processes
- IV. Analysis of culture media



Favorable External Environment In Japan

iPSCs Discovered in Japan

The Nobel Prize in Physiology or Medicine (2012)
Shinya Yamanaka, M.D, Ph.D (Professor at Kyoto University)

Expedited Regulatory Framework

- Conditional and time limited authorization system
- SAKIGAKE (fast-track designation)

Precision Manufacturing in Cell Therapy

- Clinical and scale-up infrastructure for commercial purposes

Intrinsic Healios Strengths

Established Innovative R&D Expertise

- First in human iPSC technology in the world
- Proprietary hypo-immune universal donor iPSC platform technology
- Kobe Research Institute: > 30 Ph.D. holders
- Numerous high-profile R&D partnerships & JVs

Robust CMC Expertise & Foundational Alliances with Global Players

- GCTP/GMP manufacturing facility
- Automated 3D bioreactor system for eNK
- Advanced 3D organ manufacturing
- Long-standing alliances with Nikon & Sumitomo Pharma Co., Ltd.

Clinical Development Capabilities

- Completed enrolment in two major trials in 2021 including the largest Japanese cell therapy trial in history

January 2021 Saisei Bioventures, L.P. (Saisei Fund) established by Healios

Important informational insights

Building relationships with promising companies

High return investments

Engage deeply with regenerative medicine innovation around the world through our venture fund activities

Saisei Fund partners




Jonathan Yeh (Ph.D. MBA)
 Founding Partner
 Investment Committee
 Board of Managers
 Director of GP



Hikaru Saito (Ph.D.)
 Japan representative partner
 (Appointed in Jan 2023)
 Formerly at Astellas Venture Management
 Cell & gene specialist

Investment Portfolio



Japan Investment Corporation has made a \$30 million commitment as a limited partner in the Saisei Fund, and in connection with this, Healios has decided to change its previously disclosed use of funds.

The decision by Japan Investment Corporation to invest in Saisei Bioventures, L.P. Change in the use of funds

May 12, 2017, 1st Quarter Financial Results Briefing (page 7)

Comp
ounds

BBG



Transfer our business relating to an ophthalmic surgical adjuvant containing BBG250

[The transferee] D. Western Therapeutics Institute, Inc.

[Transfer price] A lump sum fee of 1.3 billion yen at the time of transfer.


There is also the possibility of receiving milestone payments in line with the progress, etc., of development and out-licensing operations.

[Business transfer due date] April 30, 2017

Expected to receive milestone payments (amount undisclosed) as progress in development is expected in the medium term.

※February 13, 2023, D. Western Therapeutics Institute, Inc. “事業計画及び成長可能性に関する事項”(page.57 Japanese only)

MultiStem® Inflammatory Conditions







Expected effects of HLCM051 (MultiStem®), bone marrow-derived somatic stem cells

- Relief of inflammation, regulation of immune function
- Promotion of angiogenesis
- Promote protection and repair of injured cells and tissues
- Improvement of lung tissue and respiratory function

Inflammatory cells are released




Inflammatory cells attack the lungs



The inflammatory cells attack the lungs. As a result, hypoxia develops and the patient falls into severe respiratory failure.


HLCM051 administered



- **Suppresses excessive inflammation in the lungs.**
- **Protects damaged tissue and facilitates healing.**

HLCM051 accumulates in the lungs as a result of intravenous administration.


Lung function improves



We can anticipate earlier ventilator removal and a lower mortality rate.

In the matched historical data comparison, the VFD was prolonged by 8.1 days (mean), and the mortality rate was 33.7% lower (reflecting a 56% decline in mortality as compared to the historical data group).

| | Compared with historical data | |
|-------------------------------------------------------------------------------------------|-------------------------------|-------------------------|
| | HLCM051 | Matched historical data |
| Primary Endpoint | | |
| VFD (the number of days out of 28 during which a ventilator was not used for the patient) | 14.8 days | 6.7 days |
| Secondary Endpoint | | |
| Mortality (180 days after administration) | 26.3% | 60.0% |



Results of Double-blind Study Conducted by Athersys <ARDS>



Based on one-year follow-up summary results, an evaluation of quality-of-life suggests further potential benefits from MultiStem treatment including faster rehabilitation.

No serious adverse events were observed.

Analysis of the Double-blind study conducted by Athersys

| | MultiStem | Placebo |
|-------------------------------------|-----------|----------|
| Mortality | 25% | 40% |
| Ventilator-free (VF) days | 12.9 days | 9.2 days |
| Intensive Care Unit (ICU) free days | 10.3 days | 8.1 days |

Post-hoc Analysis of patients in severe condition and pneumonia-induced ARDS

| | MultiStem | Placebo |
|-------------------------------------|-----------|----------|
| Mortality | 20% | 50% |
| Ventilator-free (VF) days | 14.8 days | 7.5 days |
| Intensive Care Unit (ICU) free days | 12.0 days | 5.0 days |

In the above analysis based on data obtained 90 days after administration, the mortality rate and the number of ventilator-free days (VFD) within a 28-day post-administration period et al. tended to improve in the MultiStem group compared with the placebo group. The results of the 1-year follow-up after administration showed a similar trend.

Overview of the Analysis

| | |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical trial | Exploratory clinical trial (Phase 1/2) conducted by Athersys in US and UK (MUST-ARDS study) |
| Subjects | ARDS patients administered MultiStem or Placebo intravenously (In Phase 2 trial, MultiStem 20, Placebo 10) |
| Endpoints | <ul style="list-style-type: none"> - Mortality - Ventilator Free days (The number of the days out of 28 in which a ventilator was not used for the patient) - ICU Free Days (The number of the days out of 28 in which the patient was out of Intensive Care Unit) |

【Reference】

Research contents on MultiStem's mechanism of modulating the inflammatory response in critical care indications Published in Scientific Reports (Link to [Athersys' Website](#) June 30, 2021)

Report of Placebo-Controlled Clinical Trial Evaluating MultiStem Cell Therapy for ARDS Published in Intensive Care Medicine (Link to [Athersys' Website](#) November 30, 2021)

HLCM051 can be the first available therapeutic medicine for ARDS

- Currently only artificial respiration and ECMO (Extracorporeal Membrane Oxygenation) are available as coping therapies.
- ECMO has a limited number of installations at medical institutions, requires multiple medical staff with special skills, and has a high cost of management.

Contribution to patients ⇒ Providing new treatment Improvement of mortality and QOL

- Improving patient lifesaving rate and QOL
- Shortening the treatment period (ICU use, length of hospital stay, etc.)

Contribution to medical ⇒ Reducing the burden on medical staff and hospitals

- Improving effective use of artificial respiration including ECMO
- Curbing medical resources per patient




ECMO




Artificial Respiration

The number of patients in Japan targeted for HLCM051 is estimated to be 62,000 a year



(Source) Healios estimated the annual number of new patients with ischemic stroke in Japan according to materials issued by the Fire and Disaster Management Agency, the Ministry of Internal Affairs and Communication, and the Ministry of Health, Labour and Welfare – DATAMONITOR epidemiological estimates also shown as upper end of range.


(Source) Healios estimated the percentage of patients who reach the hospital within 36 hours after onset at 47% according to the results of its market research.




(Source) This figure was based on Stroke. 2018 May;49(5):1058-1065.Fig.2

Changes in the one year improvement rate in the HLCM051 and placebo groups


Excellent outcome




Global Recovery



BI >=95



iPSC eNK Immuno-Oncology



Key Facts about Cancer and the Unmet Need

- Solid tumors are the number one cause of death in Japan (~90% of cancer deaths)
- Cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020¹
- The economic impact of cancer is significant and increasing: The total annual economic cost of cancer in 2010 was estimated at US\$ 1.16 trillion¹

The Potential for Natural Killer (NK) Cells

- Offer tremendous promise as a new therapeutic approach to treating solid tumors.
- Innate, central role in a cell mediated defense system in humans, and attack cancer cells and virus-infected cells.
- Reported advantages over T cell-based therapies:
 - Broad mechanism to recognize tumor cells
 - Fewer adverse effects (e.g. CRS & GVHD)
 - Less exhaustion

¹<https://www.who.int/news-room/fact-sheets/detail/cancer>

Contribute to the eradication of solid tumors and other cancers by leveraging Healios' iPS cell expertise and augmenting the innate cancer killing ability of NK cells

Research & Development

- **Advanced technology at Healios' Kobe Research Institute**
 - In-house implementation from gene editing through to process development
- **Establishment of data for conducting clinical trials**
 - Generation and accumulation of efficacy and safety data

Manufacturing



- **Manufacturing Capabilities**
 - In-house production of clinical product in proprietary 3D system

Alliances & Collaborations

- **Joint Development / Partnering**
 - Maximize the potential of the eNK cell program and platform

Accelerate activities in the above three areas



eNK only



Bright green: apoptotic cells



eNK cells have killed the cancer cells

eNK with anti-EGFR antibody



The lung cancer cells were efficiently killed and the lung cancer cell spheroid was destroyed.

Anti-EGFR antibody only




The cancer cells survived and the cancer cell spheroid expanded for 86 hours.

(Source) in-house data

eNK cells have demonstrated a robust anti-tumor effect on lung cancer patient-derived tumor organoids (F-PDO®)

eNK cells were co-cultured with F-PDO® in effector/tumor cell (E:T) ratios of 1:1, 3:1 and 10:1. Cytotoxic activity was determined by measuring the apoptosis (cell death) of the cancer cells by caspase-3/7 activity.



eNK Cells effective against F-PDO®

Under conditions of co-culture with eNK cells, F-PDO® cancer cell apoptosis was observed from 8 hours (E:T=10:1) and 18 hours (E:T=3:1 and 1:1)

Under conditions of co-culture without eNK cells, the apoptosis was not observed until 42 hours.

The above graph provides data for one example. In this study, several F-PDOs were examined and generally obtained similar results.

F-PDO® :

It stands for Fukushima Patients Derived Tumor Organoid, a cell mass established at Fukushima Medical University. The F-PDO is a cell mass consisting of multiple cell types derived from patient tumor tissue. Histological and genetic analysis have confirmed that they maintain the properties of patient cancer tissue. Due to their similarity to the original cancer, the results of the effect of anti-tumor drugs in models utilizing F-PDO can be evaluated as more reflective of the clinical situation.





Photo by Fukushima Medical University

* This examination was commissioned by Healios to the Fukushima Translational Research Foundation and conducted at FUJIFILM Wako Bio Solutions Corporation.



(Source) in-house data




Maximize the potential of the eNK cell program and platform



We are pursuing partnerships with pharmaceutical companies, to access financial and other resources as well as to leverage technological synergies.


We aim to accelerate our research and development to deliver new immunology therapies using eNK cells to patients as soon as possible.

Universal Donor Cell (UDC) Replacement Therapies



¹Future migration to UDC platform


World-leading engineered “universal” iPSC platform: “UDC”




Targeted cell programming through gene-editing

- In October 2020, Healios established a clinical grade universal donor IPS cell line that can be clinically applied to humans in each of Japan, the United States and Europe.
- Master Cell Bank established in 2021
- Healios has led the development of high-quality, universal donor iPS cells in accordance with global standards.
- Consultations with the FDA and PMDA led to no concerns in relation to clinical use of UDC derived therapeutics.
- The UDC line differentiates readily into various in-house made cells (e.g. NK cells, liver progenitor cells, vascular endothelial cells, etc.).


Universal Donor Cells (UDC)




Photoreceptor cells




Pancreatic β cells



RPE cells



Liver buds



Successfully differentiated from UDCs

Future migration to UDC platform

(Source) in-house data and Joint research data



Healios

< Contact information >

IR & Finance and accounting Div.
HEALIOS K.K.

Press contact: pr@healios.jp
Investor contact: ir@healios.jp
<https://www.healios.co.jp/contact/>